Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ondine Biomedical, Inc. ( (GB:OBI) ).
Ondine Biomedical and Mid Yorkshire Teaching NHS Trust have received the Excellence in Healthcare Partnership Award for a local project that used Ondine’s Steriwave nasal photodisinfection technology to cut surgical site infections in orthopaedic procedures, achieving a reported 71% reduction in hip surgery infections and eliminating observed infections in knee surgery during the evaluation period, while also delivering cost savings. The recognition, along with the partnership’s shortlisting for the HSJ Partnership Awards, underscores growing NHS interest in non-antibiotic infection-prevention solutions amid rising concerns over antimicrobial resistance, and supports wider adoption of Steriwave across English hospitals through Ondine’s distribution partner Mölnlycke Health Care.
The most recent analyst rating on (GB:OBI) stock is a Sell with a £8.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Spark’s Take on GB:OBI Stock
According to Spark, TipRanks’ AI Analyst, GB:OBI is a Underperform.
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
To see Spark’s full report on GB:OBI stock, click here.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specialising in light-activated antimicrobial therapies, known as photodisinfection, aimed at preventing and treating infections, including those caused by multidrug-resistant organisms. Its proprietary Steriwave nasal photodisinfection system is approved in multiple international markets and is being clinically evaluated in the US, with a broader pipeline targeting indications such as chronic sinusitis, ventilator-associated pneumonia and burns.
Average Trading Volume: 213,921
Technical Sentiment Signal: Sell
Current Market Cap: £44.06M
Learn more about OBI stock on TipRanks’ Stock Analysis page.